Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/11/2020
SIETES contiene 93161 citas

 
 
<< anterior 21 a 40 de 253 siguiente >>
Presentar resultados
Seleccionar todas
21.Enlace a cita original Cita con resumen
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon Ch, Harden M, Lennon N, Gabriel S, Rodig S, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217-21. [Ref.ID 101662]
22.Enlace a cita original
Pfeffer MA, McMurray JJV. Lessons in uncertainty and humility — Clinical trials involving hypertension. N Engl J Med 2016;375:1756-66. [Ref.ID 100966]
24. Cita con resumen
25. Cita con resumen
Anónimo. FDA grants Biogen fast-track designation for Alzheimer’s drug. Kaiser Health News 2016:1. [Ref.ID 100625]
27. Cita con resumen
Moore N. Lessons from the fatal French study BIA-10-2474. BMJ 2016;353:i2727. [Ref.ID 100424]
28. Cita con resumen
Casassus B. New report on drug trial disaster in France. Lancet 2016;387:2187. [Ref.ID 100334]
29. Cita con resumen
Casassus B. France releases interim report on drug trial disaster. Lancet 2016;387:634-5. [Ref.ID 100049]
30. Cita con resumen
Casassus B. France investigates drug trial disaster. Lancet 2016;387:326. [Ref.ID 99978]
31. Cita con resumen
Anónimo. One dead, five hospitalized in French clinical trial. DIA Daily 2016:19 de enero. [Ref.ID 99970]
32. Cita con resumen
Glund S, Stangier J, Schmohl M, Gansser D, Norris S, Van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J. Articles Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386:680-90. [Ref.ID 99494]
33.Tiene citas relacionadas Cita con resumen
Kimmelman J. The secret realm of phase I trials in healthy volunteers. BMJ 2015;350:h3444. [Ref.ID 99219]
34.Tiene citas relacionadas Cita con resumen
Emanuel EJ, Bedarina G, Macci K, Gabler NB, Rid A, Wendler D. Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies. BMJ 2015;350:h3271. [Ref.ID 99218]
35. Cita con resumen
Dyer O. Experimental drug that injured UK volunteers resumes in human trials. BMJ 2015;350:h1831. [Ref.ID 98941]
36.Tiene citas relacionadas Cita con resumen
Anónimo. Experimental Alzheimer’s treatment slows cognitive decline in early trial. DIA Daily 2015:23 de marzo. [Ref.ID 98868]
37. Cita con resumen
Anónimo. Joint pain pauses Merck Ebola vaccine’s phase I. DIA Daily 2014:12 de diciembre. [Ref.ID 98386]
38. Cita con resumen
Koenekoop RK, Sui R, Sallum J, van der Born LI, Ajlan R, Khan A, den Hollander AI, Cremers FPM, Mendola JD, Bittner AK, Dagnelie G, Schuchard RA, Saperstein DA. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial. Lancet 2014;384:1513-20. [Ref.ID 98252]
39. Cita con resumen
Anónimo. Drug manufacturers race to cure Ebola. DIA Daily 2014:20 de octubre. [Ref.ID 98121]
40. Cita con resumen
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu W-J, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17. [Ref.ID 98106]
Seleccionar todas
 
<< anterior 21 a 40 de 253 siguiente >>